Concepedia

Andreas Port

AP

9

Publications

500

Citations

9

H-Index

2001

Active since

Affiliations

Novartis (Switzerland)(Current)

Merck (Germany)

Focus (Germany)

Ono Pharmaceutical (United States)

Boehringer Ingelheim (Germany)

Andreas Port is an author at Novartis (Switzerland) specializing in medicine, pharmacotherapy, and pharmacokinetics.

ORCID

Top concepts

Publications per year

2001–2021

9

Publications

9

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin <sup>*</sup>

Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port et al. · Diabetes Obesity and Metabolism · 2011 · 185 citations

Effect of Rifampin on Apparent Clearance of Everolimus

John M. Kovarik, Stefan Hartmann, Joaquim Figueiredo et al. · Annals of Pharmacotherapy · 2002 · 78 citations

Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

John M. Kovarik, Stefan Hartmann, Michael G. Bartlett et al. · Biopharmaceutics & Drug Disposition · 2007 · 51 citations

Pharmacokinetic Evaluation of Three Different Intramuscular Doses of Nandrolone Decanoate: Analysis of Serum and Urine Samples in Healthy Men

Wilma M. Bagchus, Jean Smeets, H.A.M. Verheul et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 46 citations

, , +13

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

Andreas Port, Jamie Shaw, Lena Klopp‐Schulze et al. · Pharmacology Research & Perspectives · 2021 · 44 citations · Full text

Rows per page

1–5 of 9